Featured News

July 9th, 2020

HemoShear Therapeutics Achieves Milestone in Exclusive Drug Discovery Collaboration with Horizon Therapeutics in Gout

Read More »
June 24th, 2020

HemoShear Therapeutics Receives FDA Clearance of IND for Phase 2 Study of its Investigational Drug HST5040 for the Treatment of Methylmalonic Acidemia and Propionic Acidemia

Read More »
June 4th, 2020

Shear Insights: Journal Publishes HemoShear Models for Rare Metabolic Diseases

Read More »
November 14th, 2019

Shear Insights: HemoShear Therapeutics Engages with European Metabolic Disease Consortium

Read More »
September 25th, 2019

HemoShear Therapeutics Appoints Brian A. Johns, PhD, Chief Scientific Officer

Read More »
September 20th, 2019

Prestigious Journal Publishes HemoShear Research on Gene Expression and Liver Disease

Read More »
August 23rd, 2019

Takeda And HemoShear Therapeutics: The NASH Collaboration

Read more at Seeking Alpha
June 19th, 2019

HemoShear Therapeutics Names Biopharma Veteran Kathleen M. Metters, PhD, to Board of Directors

Read More »
April 17th, 2019

Q&A on HemoShear’s 3D model of the tumor microenvironment

Read more at DDN News
March 20th, 2019

Takeda and HemoShear Therapeutics Extend Exclusive Drug Discovery Partnership in Liver Diseases

Read More »
March 6th, 2019

HemoShear Therapeutics Physiological Human Tumor Model Published in Lab on a Chip Journal

Read More »
January 3rd, 2019

Horizon Pharma Plc and HemoShear Therapeutics Enter Into Exclusive Drug Discovery Collaboration in Gout

Read More »
View More +



HemoShear Therapeutics, Inc.
501 Locust Avenue
Suite 301
Charlottesville, Virginia 22902